<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02900924</url>
  </required_header>
  <id_info>
    <org_study_id>MIMICS-3D</org_study_id>
    <nct_id>NCT02900924</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D</brief_title>
  <acronym>MIMICS-3D</acronym>
  <official_title>A Prospective, Multicentre Observational Study to Evaluate the BioMimics 3D Self-Expanding Stent System in the Treatment of Peripheral Arterial Disease: MIMICS-3D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veryan Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veryan Medical Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MIMICS-3D study will evaluate safety, effectiveness and device performance within a
      real-world clinical population of patients undergoing femoropopliteal intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MIMICS-3D study is a prospective, multicentre, observational study of the BioMimics 3D
      Stent System in patients undergoing endovascular intervention to relieve symptomatic
      peripheral arterial disease of the femoropopliteal artery. The study is designed to enable
      the collection, analysis and reporting of data from &quot;real-world&quot; use of the BioMimics 3D
      Stent System used in accordance with the Instructions for Use (IFU) associated with the
      product's CE Mark approval.

      Data collection will include that relating to safety, effectiveness and device performance
      and the period of observation during which data will be collected will extend from the index
      procedure through 3 years (36 months), according to the standard follow-up practice of the
      enrolling institution.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from a composite of major adverse events (MAE) (Primary Safety Endpoint)</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants free from composite of major adverse events (MAE) comprising death, any major amputation performed on the index limb or clinically-driven target lesion revascularization (CDTLR) through 30 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from clinically-driven target lesion revascularization (CDTLR) (Primary Effectiveness Endpoint)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants free from clinically-driven target lesion revascularization (CDTLR) through 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute technical success defined as achievement of a final residual diameter stenosis ≤30% at the end of the procedure</measure>
    <time_frame>Procedural</time_frame>
    <description>Number of participants with final residual diameter stenosis ≤30% at the end of the index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute procedural success defined as acute technical success and absence of peri-procedural adverse events.</measure>
    <time_frame>72 hours</time_frame>
    <description>Number of participants with acute technical success and absence of the following adverse events: death, stroke, myocardial infarction, acute onset of limb ischemia, index bypass graft or treated segment thrombosis, and/or need for urgent/emergent vascular surgery, within 72 h of the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of individual components of MAE</measure>
    <time_frame>30 days, 12, 24 and 36 months</time_frame>
    <description>Incidence of individual components of MAE (death, any major amputation performed on the index limb or CDTLR) through 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall rate and incidence of adverse events from Day 0 through completion of study follow-up at Month 36.</measure>
    <time_frame>36 months</time_frame>
    <description>Overall rate and incidence of all adverse events reported from Day 0 through completion of study follow-up at Month 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent patency</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>Stent patency rate assessed by duplex ultrasound, as available, determined at Months 12, 24 and 36. This will be assessed using values of peak systolic velocity ratio (PSVR) &gt;2.0, &gt;2.4; &gt;2.5; and &gt;3.5 each to indicate loss of patency on duplex ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford Clinical Category</measure>
    <time_frame>Baseline, Day 30, Months 12 24 and 36</time_frame>
    <description>Comparison of Rutherford Clinical Category measured at Baseline, Day 30, Months 12 24 and 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome (ankle brachial index (ABI) measurement)</measure>
    <time_frame>Baseline, Day 30, Months 12, 24 and 36.</time_frame>
    <description>Comparison of the ankle brachial index (ABI) measurement at Baseline, within 30 days after index procedure, then at Months 12, 24 and 36.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioMimics 3D Stent</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who receive treatment with Veryan's BioMimics 3D Stent System in accordance with
        the current approved CE Mark indication for use as stated in the Instructions for Use (IFU)
        will be consecutively enroled in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is age ≥18 and ≤85 years at date of consent.

          -  Patient has provided written informed consent for participation in the study prior to
             index procedure.

          -  Patient has documented symptomatic peripheral arterial disease scheduled for treatment
             with the BioMimics 3D stent in accordance with the approved CE Mark indication and
             Instructions for Use (IFU)

        Exclusion Criteria:

          -  Patients whose lesions cannot be crossed with a wire and/or balloon catheter and
             cannot be dilated sufficiently to allow passage of the delivery system.

          -  Patients with a history of intolerance or adverse reaction to antiplatelet and/or
             anticoagulation therapies, bleeding diathesis, severe hypertension or renal failure.

          -  Patients with known hypersensitivity to nickel-titanium.

          -  Patient has a comorbidity that in the Investigator's opinion would limit life
             expectancy to less than 12 months.

          -  Patient is pregnant or breastfeeding.

          -  Patient is unable or is unwilling to comply with site standard of care procedures and
             follow-up visit schedules for patients undergoing femoropopliteal intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Lichtenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Arnsberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Blythe Lindsay, PhD</last_name>
    <email>mimics3d@veryanmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>OLV Hospital</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lieven Maene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA Vascular Clinic/ZNA Stuivenburg Hospital</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AZ Sint Blasius</name>
      <address>
        <city>Dendermonde</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Koen DeLoose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Willem Willaert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regionaal Vaartcentrum , AZ Helig Hart Tienen</name>
      <address>
        <city>Tienen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Koen Keirse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinen-Hospital</name>
      <address>
        <city>Arnsberg-Hüsten</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaets-Herzzentrum Freiburg-Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Zeller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KEH Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jens Stegemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Klamroth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Buchholz</name>
      <address>
        <city>Buchholz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Klaus Hertting, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden-Friedrichstadt, Städtisches Klinikum</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sebastian Schellong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christos Rammos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CCB im Agaplesion Bethanien Krankenhaus</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Piorkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans Krankenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UKE (University Hospital Hamburg)</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sebastian Debus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrej Schmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gefäßpraxis im Tal</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter von Bilderling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marienhospital Osnabrück GmbH</name>
      <address>
        <city>Osnabruck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulrich Sunderdiek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RoMed Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gunnar Tepe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SRH-Klinikum Zentralklinikum Suhl</name>
      <address>
        <city>Suhl</city>
        <zip>98527</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Volker Sesselmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72016</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roland Syha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MMPJ Reijnen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Reinoud Bokkers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nuno Dias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>September 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAD</keyword>
  <keyword>PVD</keyword>
  <keyword>SFA stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

